Trial Profile

A Multi-Center, Open-Label, Phase 1/2 Clinical Trial to Evaluate the Safety and Anti-Tumor Activity of AB-101 Monotherapy and AB-101 With Immunotherapy in Patients With Relapsed/Refractory Non-Hodgkin Lymphoma of B-Cell Origin

Status: Active, no longer recruiting

Phase of Trial: Phase I/II

Latest Information Update: 17 Jun 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs AB 101 Artiva Biotherapeutics (Primary) ; Bendamustine (Primary) ; Cyclophosphamide (Primary) ; Fludarabine (Primary) ; Interleukin-2 (Primary) ; Rituximab (Primary)
Indications B-cell lymphoma; Diffuse large B cell lymphoma; Non-Hodgkin's lymphoma
Focus Adverse reactions; First in man; Therapeutic Use
Sponsors Artiva Biotherapeutics

11 Jun 2025 Planned End Date changed from 1 Nov 2024 to 31 Dec 2025.
11 Jun 2025 Status changed from recruiting to active, no longer recruiting.
13 May 2025 According to an Artiva Biotherapeutics Media Release, the data from this study were published at the American Society of Gene & Cell Therapy (ASGCT) 28th annual meeting.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com